Physician profile
Lawrence Alan Miller
NPI 1912116732
$6,899.35
in general payments reported to CMS, 2019-2025
38 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $801 · 2021: $1,625 · 2022: $1,237 · 2023: $781 · 2024: $886 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,505.40 | 2019-2025 | |
| Celgene Corporation | $625.38 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $462.22 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $417.81 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.40 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $343.72 | 2019-2025 | |
| Janssen Biotech, INC. | $330.53 | 2019-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $185.09 | 2019-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $163.72 | 2019-2024 | Suflave |
| Boston Scientific Corporation | $122.13 | 2019 | |
| Amgen INC. | $115.02 | 2020-2023 | Avsola, Amjevita |
| Ucb, INC. | $109.66 | 2019-2020 | |
| Ardelyx, INC. | $100.16 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $96.53 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $95.25 | 2020-2023 | Rebyota |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $88.14 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $84.92 | 2022-2024 | Dupixent |
| Alfasigma USA, INC. | $84.31 | 2020-2021 | |
| Organon LLC | $71.97 | 2021-2025 | Hadlima |
| Pentax of America, INC. | $63.18 | 2022 | |
| Daiichi Sankyo INC. | $47.08 | 2019-2024 | Injectafer |
| Echosens North America, INC. | $45.44 | 2022-2024 | Fibroscan |
| Ethicon US, LLC | $33.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $32.95 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $30.07 | 2019-2021 | |
| Genzyme Corporation | $29.61 | 2023 | |
| Digestive Care, INC. | $26.41 | 2021 | |
| Intercept Pharmaceuticals, INC. | $22.29 | 2025 | |
| Shionogi INC | $21.54 | 2019 | |
| Olympus America INC. | $20.98 | 2021 | |
| Endo Pharmaceuticals INC. | $20.66 | 2020 | |
| Redhill Biopharma INC. | $19.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.82 | 2023 | Linzess |
| Sandoz INC. | $15.70 | 2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $14.36 | 2025 | Zenpep |
| Allergan, INC. | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,560.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.